Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NAMDIATREAM

Financiado

Cerrado

NANOTECHNOLOGICAL TOOLKITS FOR MULTI MODAL DISEASE DIAGNOSTICS AND TREATMENT MON...

NANOTECHNOLOGICAL TOOLKITS FOR MULTI MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset i... ver más

30/06/2014

TRINITY COLLEGE DU...

17M€

Presupuesto del proyecto: 17M€

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-06-30 No tenemos la información de la convocatoria

0% 73% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

TRINITY COLLEGE DUBLIN

0.00€ | Lider

MPG

N.D. | Participante

USMB

N.D. | Participante

TECHNISCHE UNIVERSITAET BRAU...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NanoNIR Development of a fluorescence based nanotool for early breas... 181K€ Cerrado

EUIN2015-62619 DISPOSITIVOS EN LA FRONTERA DE NANOMECANICA Y NANOOPTICA PAR... 10K€ Cerrado

MAT2015-66904-R FUSIONANDO NANOMECANICA, OPTOMECANICA Y PLASMONICA PARA LA D... 266K€ Cerrado

NanoIntra Multitasking Nanoparticles for Intracellular Bioimaging and... 259K€ Cerrado

RYC-2017-21640 Merging nanomechanical systems with other nanotechnologies t... 309K€ Cerrado

ASSAY FOR BIOMARKERS Magnetic Nanoparticles for Multiplexed Assays for Low and Hi... 177K€ Cerrado

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 17M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead, lab-on-a-chip and lab-on-a-wire nano-devices utilizing photoluminescent, plasmonic, magnetic and non-linear optical properties of nanomaterials. This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility. The ETP in Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification. We will deliver •Photoluminescent nanoparticle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment •Nanocrystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell •Multi-Parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nanowires •Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. •OECD-compliant nanomaterials with improved stability, signal strength and biocompatibility Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores